• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    argenx SE - American Depositary Shares (NQ:ARGX)

    984.95 +133.66 (+15.70%)
    Streaming Delayed Price Updated: 12:50 PM EDT, Aug 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 406,741
    Open 927.33
    Bid (Size) 983.86 (40)
    Ask (Size) 986.67 (80)
    Prev. Close 851.29
    Today's Range 925.62 - 1,002.16
    52wk Range 650.01 - 953.58
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    News headline image
    argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing ↗
    argenx (NASDAQ:ARGX) reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients... 
    Via MarketBeat
    Topics Intellectual Property

    Performance

    YTD
    +17.3%
    +17.3%
    1 Month
    +14.5%
    +14.5%
    3 Month
    +26.9%
    +26.9%
    6 Month
    +16.8%
    +16.8%
    1 Year
    +48.9%
    +48.9%

    More News

    Read More
    News headline image
    $100 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗
    Via Benzinga
    News headline image
    argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
    From argenx SE
    Via GlobeNewswire
    News headline image
    Here’s How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗
    Via Benzinga
    News headline image
    argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102 ↗
    Via MarketBeat
    Topics Intellectual Property
    News headline image
    argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
    From Forte Biosciences, Inc.
    Via Business Wire
    News headline image
    argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenex Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings Intellectual Property
    News headline image
    argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx to Host Autoimmune Myositis R&D Webinar
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Eyes More VYVGART Growth as Pipeline Catalysts Near ↗
    Via MarketBeat
    Topics Intellectual Property Supply Chain
    News headline image
    argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference ↗
    Via MarketBeat
    Topics Intellectual Property
    News headline image
    argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
    From argenx SE
    Via GlobeNewswire
    News headline image
    Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
    Via The Motley Fool
    News headline image
    argenx to Host Myositis R&D Webinar on June 23, 2026
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx to Present at Upcoming Investor Conferences
    From argenx SE
    Via GlobeNewswire
    News headline image
    Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
    Via The Motley Fool
    News headline image
    2 Ways to Play the Big Pharma Patent Cliff ↗
    Via MarketBeat
    Topics ETFs Intellectual Property
    News headline image
    argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Reports First Quarter 2026 Financial Results and Provides Business Update
    From argenx SE
    Via GlobeNewswire

    Frequently Asked Questions

    Is argenx SE - American Depositary Shares publicly traded?
    Yes, argenx SE - American Depositary Shares is publicly traded.
    What exchange does argenx SE - American Depositary Shares trade on?
    argenx SE - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for argenx SE - American Depositary Shares?
    The ticker symbol for argenx SE - American Depositary Shares is ARGX on the Nasdaq Stock Market
    What is the current price of argenx SE - American Depositary Shares?
    The current price of argenx SE - American Depositary Shares is 984.95
    When was argenx SE - American Depositary Shares last traded?
    The last trade of argenx SE - American Depositary Shares was at 08/17/26 12:50 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.